Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Development, formulation and quality evaluation of a lyophilized PSMA-11 kit for rapid radiolabeling with [68Ga]Gallium

Document Type : Original Article

Authors
Muhammad Fakhrurazi Ahmad Fadzil 1
Ooi Xin Yue 1
Zaitulhusna Md Safee 1
Nik Muhammad Fitri 1
Noratikah Mat Ail 1
Jaleezah Idris 2
Nor Idayu Razali 2
Hamdi Noor 2
Wan Hamirul Bahrin 3
Rahimah Rahim 3
Muhamad Faiz Othman 4
Zarif Ashhar 1
1 Pharmacy Department, Institut Kanser Negara, 4, Jalan P7, Presint 7, 62250 Wilayah Persekutuan Putrajaya, Malaysia
2 Nuclear Medicine Department, Institut Kanser Negara, 4, Jalan P7, Presint 7, 62250 Wilayah Persekutuan Putrajaya, Malaysia
3 Medical Technology Division, Malaysian Nuclear Agency, 43000 Kajang, Bangi, Malaysia
4 Faculty of Pharmacy, MARA University of Technology (UiTM), Bandar Puncak Alam, Selangor, 42300 Puncak Alam, Malaysia
10.22034/irjnm.2022.40049
Abstract
Introduction: Recently, [68Ga]Gallium lyophilized kit has been widely practiced as it simplifies the radiolabeling process. Thus, our aim is to develop, formulate and evaluate a single-vial lyophilized kit (EZYKit PSMA) for the preparation and radiolabeling of [68Ga]Ga-PSMA-11.
Methods: Two commercially available [68Ge/68Ga] Generators used in this study were from ITG and Eckert & Ziegler with a current [68Ga]Gallium elution activity of 222 MBq and 1480 MBq, respectively. Initially, EZYkit-PSMA radiolabeling parameters were optimized, and the Glass Transition Temperature (Tg) of the optimized PSMA-11 formulation was determined. Quality assessment of EZYkit-PSMA, including physical appearance, quantitative assay of the active ingredient, radiochemical purity, pH, sterility, endotoxin, and storage stability, were also established.
Results: Optimization of radiolabeling parameters showed that the highest radiochemical purity was achieved with 0.35 ml and 0.75 ml of 1.5 M acetate buffer and 10 µg PSMA-11 for both ITG and Eckert & Ziegler Generator, respectively. The quality assessment results of EZYkit-PSMA were within the specifications except for the physical appearance, where it appears to be structurally collapsed. This study discussed two main factors that contributed to the collapsed lyophilized cake.
Conclusion: Despite the physical appearance, EZYkit-PSMA was successfully developed, and the quality meets the pharmaceutical standards. EZYkit-PSMA showed high stability over 6 month's storage period in both the fridge and freezer. Overall, using EZYkit-PSMA for radiolabeling with [68Ga]Gallium simplified the whole radiolabeling procedure and reduces process time and error with high labelling yield and efficiency.
Keywords
Gallium-68
Lyophilized EZYkit
Prostate specific membrane antigen
Prostate cancer
Subjects
  1. Azizah AM, Nor Saleha IT, Noor Hashimah A, Asmah ZA, Mastulu W. Malaysian National Cancer Registry Report 2007-2011: Malaysia Cancer Statistic, Data and Figure. J Natl Cancer Inst. 2016. [cited 2022 Nov 18]. Available from: https://www.crc.gov.my/wp-content/uploads/documents/report/MNCRRrepor2007-2011.pdf
  2. Gourni E, Henriksen G. Metal-based PSMA radioligands. Molecules. 2017 Mar 24;22(4):523.
  3. Velikyan I. Continued rapid growth in 68Ga applications: update 2013 to June 2014.
    J Label Compd Radiopharm. 2015 Mar;58(3):99-121.
  4. Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of Tc‐99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga‐68 PSMA PET/CT. Prostate. 2017 Aug;77(11):1205-12.
  5. Zhang Z, Zhu Z, Yang D, Fan W, Wang J, Li X, Chen X, Wang Q, Song X. Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer. Oncol Lett. 2016 Aug 1;12(2):1001-6.
  6. Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5(12):1388.
  7. Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017 Mar 1;58(3):425-31.
  8. Seitzer KE, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, Rahbar K. Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. Cancers. 2021 Jul 23;13(15):3715.
  9. Ashhar Z, Yusof NA, Ahmad Saad FF, Mohd Nor SM, Mohammad F, Bahrin Wan Kamal WH, Hassan MH, Ahmad Hassali H, Al-Lohedan HA. Preparation, characterization, and radiolabeling of [68Ga] Ga-NODAGA-Pamidronic acid: a potential PET bone imaging agent. Molecules. 2020 Jun 9;25(11):2668.
  10. Shetty D, Lee YS, Jeong JM. 68Ga-labeled radiopharmaceuticals for positron emission tomography. Nucl Med Mol Imaging. 2010 Dec;44(4):233-40.
  11. Satpati D, Shinto A, Kamaleshwaran KK, Sane S, Banerjee S. Convenient preparation of [68Ga] DKFZ-PSMA-11 using a robust single-vial kit and demonstration of its clinical efficacy. Mol Imaging Biol. 2016 Jun;18(3):420-7.
  12. Fadzil MF, Najah MK, Yen N, Janib SN, Khairullah NH. Purification and concentration of gallium-68 via anion exchange method from a SnO2-based column germanium-68/gallium-68 generator. J Nucl Related Technol. 2015 Jun 30;12(01):1-8.
  13. Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application. Nucl Med Commun. 2010 Aug 1;31(8):753-8.
  14. Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules. 2015 Jul 16;20(7):12913-43.
  15. Patel SM, Nail SL, Pikal MJ, Geidobler R, Winter G, Hawe A, Davagnino J, Gupta SR. Lyophilized drug product cake appearance: what is acceptable?. J Pharm Sci. 2017 Jul 1;106(7):1706-21.
  16. Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, Mokaleng B, Zeevaart JR, Sathekge M. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015 Aug 14;20(8):14860-78.
  17. Baudhuin H, Van Bockstal PJ, De Beer T, Vaneycken I, Bridoux J, Raes G, Caveliers V, Keyaerts M, Devoogdt N, Lahoutte T, Xavier C. Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for 68Ga-labeling. Eur J Pharm Biopharm. 2021 Sep 1;166:194-204.
  18. Nautiyal U, Singh S, Singh R, Gopal KS. Fast dissolving tablets as a novel boon: a review. J Pharm Chem Biol Sci. 2014;2(1):5-26.
  19. Depaz RA, Pansare S, Patel SM. Freeze-drying above the glass transition temperature in amorphous protein formulations while maintaining product quality and improving process efficiency. J Pharm Sci. 2016 Jan 1;105(1):40-9.
  20. Nail SL, Jiang S, Chongprasert S, Knopp SA. Fundamentals of freeze-drying. In: Nail SL, Akers MJ, editors. Development and manufacture of protein pharmaceuticals. 1st ed. New York: Springer; 2002:281-360.
  21. Golan H, Esa M, Moshkoviz K, Feldhaim A, Hoch B, Shalom E. Enhancing capacity and synthesis of [68Ga] 68-Ga-PSMA-HBED-CC with the lyophilized ready-to-use kit for nuclear pharmacy applications. Nucl Med Commun. 2020 Sep 1;41(9):986-90.
  22. Roesch F. Maturation of a key resource–the germanium-68/gallium-68 generator: development and new insights. Curr Radiopharm. 2012 Jul 1;5(3):202-11.